MCID: SML001
MIFTS: 52

Small Cell Carcinoma

Categories: Cancer diseases, Genetic diseases, Rare diseases, Respiratory diseases, Skin diseases

Aliases & Classifications for Small Cell Carcinoma

MalaCards integrated aliases for Small Cell Carcinoma:

Name: Small Cell Carcinoma 12 15 17
Small Cell Carcinoma, Intermediate Cell 12 70
Small Cell Carcinoma - Intermediate Cell 12
Intermediate Cell Small Cell Carcinoma 12
Small Cell Carcinoma of Lung 70
Carcinoma, Small Cell 70

Classifications:



External Ids:

Disease Ontology 12 DOID:0050685
NCIt 50 C4099
SNOMED-CT 67 5958006
UMLS 70 C0149925 C0262584 C0334239

Summaries for Small Cell Carcinoma

Disease Ontology : 12 A carcinoma that is an undifferentiated neoplasm composed of primitive-appearing cells.

MalaCards based summary : Small Cell Carcinoma, also known as small cell carcinoma, intermediate cell, is related to ovarian small cell carcinoma and lung combined type small cell carcinoma. An important gene associated with Small Cell Carcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Developmental Biology and Pathways in cancer. The drugs BCG vaccine and Bevacizumab have been mentioned in the context of this disorder. Affiliated tissues include lung, prostate and cervix, and related phenotypes are Reduced mammosphere formation and cellular

Wikipedia : 73 Small-cell carcinoma is a type of highly malignant cancer that most commonly arises within the lung,... more...

Related Diseases for Small Cell Carcinoma

Diseases in the Small Cell Carcinoma family:

Basal Cell Carcinoma 1 Basal Cell Carcinoma 2
Basal Cell Carcinoma 3 Basal Cell Carcinoma 4
Basal Cell Carcinoma 5 Basal Cell Carcinoma 6
Basal Cell Carcinoma 7 Basal Cell Carcinoma
Large Cell Carcinoma Basal Cell Carcinoma, Multiple

Diseases related to Small Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 952)
# Related Disease Score Top Affiliating Genes
1 ovarian small cell carcinoma 33.5 SYP SMARCA4 ENO2
2 lung combined type small cell carcinoma 33.1 SYP NCAM1
3 cervix small cell carcinoma 33.1 SYP ENO2 CHGA
4 gastric small cell carcinoma 32.9 SYP NCAM1 ENO2 CHGA
5 prostate small cell carcinoma 32.8 TMPRSS2 BRCA2
6 laryngeal small cell carcinoma 32.8 SYP NKX2-1 NCAM1 KIT CHGA
7 endometrial small cell carcinoma 32.7 SYP PTPRC NCAM1 KIT ENO2 CHGA
8 ureter small cell carcinoma 32.7 SYP NKX2-1 NCAM1 KRT7 ENO2 CHGA
9 gallbladder small cell carcinoma 32.5 SYP NCAM1 KRT7 ENO2 CHGA
10 lung large cell carcinoma 32.2 SYP NKX2-1 NCAM1 CHGA
11 small cell cancer of the lung 31.8 TP53 SYP PTPRC PTEN NKX2-1 NCAM1
12 lung cancer susceptibility 3 31.6 TP53 NKX2-1 KRT7 KRT20 KRT19 KRAS
13 merkel cell carcinoma 31.5 TP53 SYP PTPRC NKX2-1 NCAM1 KRT7
14 in situ carcinoma 31.3 TP53 PTEN EGFR BRCA2
15 squamous cell carcinoma 31.2 TP53 PTEN KRT7 KRT19 EGFR
16 carcinoid syndrome 31.2 SYP ENO2 CHGA CALCA
17 rhabdoid cancer 31.1 TP53 SYP SMARCA4 PTPRC
18 benign mesothelioma 31.0 NKX2-1 KRT7 KRT20 KRT19
19 ureteral benign neoplasm 30.9 SYP NKX2-1 KRT7
20 prostate cancer 30.9 TP53 TMPRSS2 SYP PTEN KRAS KLK3
21 atypical teratoid rhabdoid tumor 30.9 TP53 SYP SMARCA4 CHGA BRCA2
22 gallbladder adenocarcinoma 30.9 TP53 KRT20 EGFR
23 transitional cell carcinoma 30.9 TP53 PTEN KRT7 KRT20 KRT19 KLK3
24 pulmonary large cell neuroendocrine carcinoma 30.8 SYP NCAM1 CHGA
25 lung cancer 30.8 TP53 SYP SMARCA4 PTPRC PTEN NKX2-1
26 adenocarcinoma 30.7 TP53 PTEN NKX2-1 KRT7 KRT20 KRAS
27 large cell neuroendocrine carcinoma 30.7 SYP NKX2-1 NCAM1 KRT7 KRT20 KIT
28 thyroid gland medullary carcinoma 30.7 SYP NKX2-1 CHGA CALCA
29 suppression of tumorigenicity 12 30.7 TP53 TMPRSS2 SYP PTEN KLK3 EGFR
30 carcinoid tumors, intestinal 30.7 SYP NKX2-1 ENO2 CHGA
31 bladder urothelial carcinoma 30.7 TP53 PTEN KRT20 KRAS
32 endocervical adenocarcinoma 30.7 TP53 KRT7 KRT20
33 neuroendocrine tumor 30.6 SYP NKX2-1 NCAM1 KRT20 KRT19 GRP
34 ductal carcinoma in situ 30.6 TP53 PTEN EGFR BRCA2
35 endodermal sinus tumor 30.6 KRT7 KLK3 CHGA
36 adenoma 30.6 TP53 SYP KRT7 KRT20 KRAS CHGA
37 constipation 30.6 KIT GRP CHGA CALCA
38 cystadenocarcinoma 30.6 TP53 PTPRC KRT7
39 cystitis 30.6 TP53 KRT7 KRT20 KIT
40 bladder cancer 30.5 TP53 PTEN KRT20 KRT19 KRAS EGFR
41 achalasia 30.5 TP53 KIT ENO2
42 mucinous cystadenocarcinoma 30.5 PTPRC KRT7 KRT20
43 lung disease 30.5 TP53 NKX2-1 GRP ENO2 EGFR
44 neuroendocrine carcinoma 30.5 SYP PTPRC PTEN NKX2-1 NCAM1 KRT7
45 thyroid carcinoma, familial medullary 30.5 NKX2-1 KRAS CHGA CALCA
46 tubular adenocarcinoma 30.5 SYP KRT7 KRT20 ENO2 EGFR CHGA
47 cholecystitis 30.4 TP53 EGFR CALCA
48 pleomorphic carcinoma 30.4 TP53 NKX2-1 KRT7 KIT EGFR
49 granular cell tumor 30.4 SYP NKX2-1 ENO2
50 ovarian mucinous neoplasm 30.4 KRT7 KRT20 KRAS

Graphical network of the top 20 diseases related to Small Cell Carcinoma:



Diseases related to Small Cell Carcinoma

Symptoms & Phenotypes for Small Cell Carcinoma

GenomeRNAi Phenotypes related to Small Cell Carcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 CHGA EGFR KRAS KRT7 NCAM1 PTEN

MGI Mouse Phenotypes related to Small Cell Carcinoma:

46 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.39 BRCA2 EGFR ENO2 KIT KRAS KRT19
2 growth/size/body region MP:0005378 10.38 BRCA2 CHGA EGFR ENO2 GRP KIT
3 cardiovascular system MP:0005385 10.36 CHGA EGFR GRP KIT KLK3 KRAS
4 endocrine/exocrine gland MP:0005379 10.33 BRCA2 CHGA EGFR KIT KRAS KRT19
5 nervous system MP:0003631 10.31 BRCA2 CHGA EGFR ENO2 GRP KIT
6 digestive/alimentary MP:0005381 10.27 BRCA2 EGFR KIT KRAS KRT19 NKX2-1
7 embryo MP:0005380 10.21 BRCA2 EGFR KIT KRAS KRT19 PTEN
8 neoplasm MP:0002006 10.2 BRCA2 EGFR KIT KRAS KRT19 NKX2-1
9 integument MP:0010771 10.18 BRCA2 EGFR KIT KRAS KRT19 PTEN
10 normal MP:0002873 10.18 BRCA2 EGFR KIT KLK3 KRAS KRT19
11 liver/biliary system MP:0005370 10.1 EGFR KIT KRAS KRT19 PTEN PTPRC
12 muscle MP:0005369 10.08 CHGA EGFR KIT KLK3 KRAS PTEN
13 limbs/digits/tail MP:0005371 10.05 BRCA2 EGFR KIT KRAS PTEN SMARCA4
14 no phenotypic analysis MP:0003012 10.01 CHGA EGFR KIT KRAS KRT19 NKX2-1
15 renal/urinary system MP:0005367 9.91 CHGA EGFR KIT KRAS KRT7 PTEN
16 reproductive system MP:0005389 9.85 BRCA2 CHGA EGFR KIT KRAS KRT19
17 pigmentation MP:0001186 9.8 EGFR KIT KRAS PTEN SMARCA4 TP53
18 respiratory system MP:0005388 9.73 EGFR ENO2 GRP KIT KRAS KRT19
19 skeleton MP:0005390 9.32 BRCA2 EGFR KIT KRAS KRT19 NKX2-1

Drugs & Therapeutics for Small Cell Carcinoma

Drugs for Small Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 185)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
BCG vaccine Approved, Investigational Phase 3
2
Bevacizumab Approved, Investigational Phase 3 216974-75-3
3
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
4
Memantine Approved, Investigational Phase 3 19982-08-2 4054
5
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
6
Belotecan Investigational Phase 3 256411-32-2
7
Camptothecin Experimental Phase 3 7689-03-4
8 Vaccines Phase 3
9 Angiogenesis Inhibitors Phase 3
10 Mitogens Phase 3
11 Endothelial Growth Factors Phase 3
12 Dopamine Agents Phase 3
13 Excitatory Amino Acid Antagonists Phase 3
14 Antiparkinson Agents Phase 3
15 Neurotransmitter Agents Phase 3
16 Hematinics Phase 3
17 Epoetin alfa Phase 3 113427-24-0
18
Vorinostat Approved, Investigational Phase 1, Phase 2 149647-78-9 5311
19
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
20
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
21
Arsenic trioxide Approved, Investigational Phase 2 1327-53-3 518740
22
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
23
Lenograstim Approved, Investigational Phase 2 135968-09-1
24
Somatostatin Approved, Investigational Phase 1, Phase 2 51110-01-1, 38916-34-6 53481605
25
Topotecan Approved, Investigational Phase 2 119413-54-6, 123948-87-8 60700
26
Talazoparib Approved, Investigational Phase 2 1207456-01-6 135565082
27
Niraparib Approved, Investigational Phase 2 1038915-60-4 24958200
28
Trastuzumab Approved, Investigational Phase 1, Phase 2 180288-69-1 9903
29
ramucirumab Approved, Investigational Phase 2 947687-13-0
30
Ceritinib Approved Phase 2 1032900-25-6
31
Crizotinib Approved Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
32
Temozolomide Approved, Investigational Phase 1, Phase 2 85622-93-1 5394
33
Rucaparib Approved, Investigational Phase 1, Phase 2 283173-50-2 9931954
34
Methyltestosterone Approved Phase 2 58-18-4 6010
35
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
36
Testosterone undecanoate Approved, Investigational Phase 2 5949-44-0
37
Testosterone enanthate Approved Phase 2 315-37-7 9416
38
Testosterone Approved, Investigational Phase 2 58-22-0 6013
39
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
40
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
41
Trametinib Approved Phase 1, Phase 2 871700-17-3 11707110
42
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4
43
Lapatinib Approved, Investigational Phase 2 231277-92-2, 388082-78-8 208908 9941095
44
nivolumab Approved Phase 2 946414-94-4
45
Ipilimumab Approved Phase 2 477202-00-9
46
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
47
Durvalumab Approved, Investigational Phase 2 1428935-60-7
48
Lamivudine Approved, Investigational Phase 2 134678-17-4 60825
49
Osimertinib Approved Phase 2 1421373-65-0 71496458
50
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 446556 60843

Interventional clinical trials:

(show top 50) (show all 209)
# Name Status NCT ID Phase Drugs
1 A Randomized Prospective Multicenter Trial of Belotecan/Cisplatin Versus Etoposide/Cisplatin in Patients With Previously Untreated, Extensive-stage Small-cell Lung Cancer Unknown status NCT00826644 Phase 3 Belotecan/Cisplatin;Etoposide/Cisplatin
2 Phase III Randomized Study of Hypofractionated vs Conventionally Fractionated Concurrent Chemo-radiotherapy for Limited Disease Small Cell Lung Cancer Unknown status NCT02688036 Phase 3
3 The SILVA Study: Survival in an International Phase III Prospective Randomized LD Small Cell Lung Cancer Vaccination Study With Adjuvant BEC2 and BCG Completed NCT00037713 Phase 3
4 Randomized Trial of Mediastinal Lymph Node Sampling Versus Complete Lymphadenectomy During Pulmonary Resection in the Patient With N0 and N1 (Less Than Hilar) Non-Small Cell Carcinoma Completed NCT00003831 Phase 3
5 A PHASE III STUDY OF ADJUVANT CHEMOTHERAPY AFTER RESECTION FOR PATIENTS WITH T2N0 STAGE I NON-SMALL CELL CARCINOMA OF THE LUNG Completed NCT00002852 Phase 3 paclitaxel;carboplatin
6 A Placebo-Controlled Study on the Effect of Epoetin Alfa in Patients With Malignancy Receiving Chemotherapy Completed NCT00270166 Phase 3 epoetin alfa
7 Role of Radiotherapy to the Primary Lesion in Metastatic Non-small Cell Lung Cancer Patients After First Line Systemic Therapy Recruiting NCT04776083 Phase 3 first line systemic therapy
8 Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab Recruiting NCT03811002 Phase 2, Phase 3 Atezolizumab;Carboplatin;Cisplatin;Etoposide
9 Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial Recruiting NCT04402788 Phase 2, Phase 3 Atezolizumab
10 MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK) Recruiting NCT04155034 Phase 3
11 A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC Recruiting NCT04214262 Phase 3 Atezolizumab
12 Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Recruiting NCT04181060 Phase 3 Osimertinib
13 EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis Recruiting NCT03793179 Phase 3 Carboplatin;Pemetrexed
14 Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO) Recruiting NCT04267848 Phase 3 Carboplatin;Cisplatin;Gemcitabine Hydrochloride;Paclitaxel;Pemetrexed Disodium
15 Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC Recruiting NCT04092283 Phase 3 Carboplatin;Cisplatin;Etoposide;Paclitaxel;Pemetrexed Disodium
16 A Phase 3, Controlled, Open-label, Randomized Study of RRx-001 Administered Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Lung Cancer Active, not recruiting NCT03699956 Phase 3 Cisplatin/carboplatin plus etoposide
17 Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers Active, not recruiting NCT02595944 Phase 3
18 Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting NCT02193282 Phase 3 Erlotinib Hydrochloride
19 A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (≥ 4 cm) - IIIA Non-small Cell Lung Cancer (NSCLC) Active, not recruiting NCT00324805 Phase 3 Cisplatin;Docetaxel;Gemcitabine Hydrochloride;Pemetrexed Disodium;Vinorelbine Tartrate
20 Phase III Trial of Stereotactic Radiosurgery (SRS) Versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or Fewer Brain Metastases From Small Cell Lung Cancer Not yet recruiting NCT04804644 Phase 3 Memantine Hydrochloride
21 Phase III Study Comparing Osimertinib Monotherapy to Combination Therapy With Osimertinib,Carboplatin and Pemetrexed for Untreated Patients With Advanced Non-squamous Non-Small Cell Lung Cancer With Concurrent EGFR and TP53 Mutations Not yet recruiting NCT04695925 Phase 3 Osimertinib 80 MG [Tagrisso];Pemetrexed 500 MG Injection;Carboplatin
22 Randomized Trial of Epoetin Alfa in Patients With Advanced Non-Small Cell Carcinoma of the Lung (EPO-CAN-20) Terminated NCT00310232 Phase 3 Epoetin Alfa
23 The Effect Of Aspirin On Survival Following Potentially Curative Resection Of Non Small Cell Carcinoma Of The Lung The Big A Trial Withdrawn NCT01058902 Phase 3 Aspirin 75 mg
24 A Randomized, Phase III Dose Response Study of Prophylactic Cranial Irradiation (PCI) for Small Cell Carcinoma of the Lung Withdrawn NCT00006344 Phase 3
25 Phase Ⅱ Study of Relationship Between UGT1A1 Gene Polymorphism and Toxicity and Efficacy of Irinotecan in Small Cell Lung Cancer Unknown status NCT01635400 Phase 2 Irinotecan
26 Phase 2 Study of Temozolomide as Maintenance Therapy After Initial Induction Chemotherapy in Small Cell Lung Cancer Unknown status NCT01900951 Phase 2 Temozolomide
27 Phase II Study of Surgery Combined With Recombinant Adenoviral Human p53 Gene Therapy in Treatment Advanced Non-small-cell Carcinoma Unknown status NCT01574729 Phase 2 Surgery combined with rAd-p53 gene therapy
28 Prospective Phase II Trial of a Combination of Gemcitabine and UFT as First-Line Treatment in Elderly Patients With Advanced Non-Small Cell Carcinoma Unknown status NCT00625352 Phase 2 Gemcitabine, UFT
29 Phase I/II Study of Vorinostat and Gefitinib in Relapsed/ or Refractory Patients With Advanced Non-small Cell Carcinoma (NSCLC) Unknown status NCT01027676 Phase 1, Phase 2 Study treatment
30 Open Label Study of Single Dose Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy Unknown status NCT00100256 Phase 1, Phase 2 Rhenium (Re 188 P2045, BAY86-5284)
31 Combination Chemotherapy With or Without Maintenance Sunitinib Malate (NSC 736511) for Untreated Extensive Stage Small Cell Lung Cancer: A Phase IB/Randomized Phase II Study Completed NCT00453154 Phase 1, Phase 2 Carboplatin;Cisplatin;Etoposide;Sunitinib Malate
32 Pilot Phase II Study of 5-Azacytidine in Previously Treated Patients With Advanced NSCLC Completed NCT01281124 Phase 2 Azacitidine
33 Phase 2 Open-Label, Multicenter Clinical Study of the Safety and Efficacy of Intravenous Administration of SNS-595 in Patients With Advanced Small Cell Lung Cancer (SCLC) Completed NCT00298896 Phase 2 SNS-595
34 An Open-label Phase II Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of a Single Dose of 200 mg i.v. BI 2536 Administered Every 21 Days in Patients With Sensitive Relapse Small Cell Lung Cancer Completed NCT00412880 Phase 2 BI 2536
35 Phase I/II Study to Investigate the Safety, Tolerability, Efficacy and Pharmacokinetics of ZK 219477 in Combination With Cisplatin as First-line Therapy in Chemotherapy-naïve Patients With Extensive-disease (ED) Stage Small-cell Lung Cancer (SCLC) Completed NCT00359359 Phase 1, Phase 2 Sagopilone (BAY86-5302, ZK 219477);Cisplatin
36 Phase II Study of Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Patients With Limited Stage Small Cell Lung Cancer Completed NCT00308529 Phase 2 irinotecan;carboplatin;bevacizumab
37 A Phase II Trial of VInflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer Completed NCT00284154 Phase 2 Vinflunine
38 A Phase I/II Study of Radiation Dose Intensity Concurrent With Chemotherapy For Limited Stage Small Cell Lung Cancer Completed NCT00126828 Phase 1, Phase 2
39 A Phase II Trial of Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer Completed NCT00294931 Phase 2 irinotecan;carboplatin;bevacizumab
40 A Phase II Trial of Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer Completed NCT00305942 Phase 2 Topotecan;carboplatin
41 Phase II Trial of ALIMTA in Relapsed Small Cell Lung Cancer Completed NCT00191750 Phase 2 Pemetrexed
42 A Phase I/II Study of Tergenpumatucel-L (HyperAcute Lung) an Antitumor Vaccination Using Alpha (1,3) Galactosyltransferase Expressing Allogeneic Tumor Cells in Patients With Refractory or Recurrent Non-Small Cell Lung Cancer Completed NCT00073398 Phase 1, Phase 2
43 A Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation Therapy for Patients With Non-small Cell Carcinoma of the Lung. (PEARL Trial) Completed NCT00391248 Phase 2 Erlotinib
44 A Pilot Phase II Protocol Of Arsenic Trioxide (Trisenox) In Subjects With Advanced Non-Small Cell Carcinoma Of The Lung Completed NCT00075426 Phase 2 arsenic trioxide
45 LCCC 0215: Induction Chemotherapy Using Paclitaxel, Carboplatin, CPT-11 With Pegfilgrastim Support Followed by Conformal Radiotherapy and Paclitaxel/Carboplatin/ZD1839 in Locally Advanced Unresectable Stage IIIA/B Non-Small Cell Carcinoma of the Lung Completed NCT00280787 Phase 2 Paclitaxel;Carboplatin;CPT-11;Pegfilgrastim
46 Phase I/II Trial of Infusional Gemcitabine in Combination With Carboplatin in Chemonaive Non-small Cell Carcinoma Completed NCT00212043 Phase 2 carboplatin and gemcitabine
47 A Randomized Trial of Pivanex Plus Docetaxel or Docetaxel Monotherapy in Patients With Chemotherapy Resistant Advanced Non-Small Cell Carcinoma of the Lung (NSCLC) Completed NCT00073385 Phase 2 Pivanex;Docetaxel
48 Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer Completed NCT01642251 Phase 1, Phase 2 Cisplatin;Etoposide;Veliparib;Placebo
49 A Clinical Trial of Increased Chest Radiotherapy Dose for Limited Stage Small Cell Lung Cancer Completed NCT00907569 Phase 2
50 A Phase II Evaluation of ABT-888 (NCI Supplied Agent: ABT-888, NSC #737664), Topotecan (NSC # 609699) and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Squamous or Non-squamous Cell Carcinoma of the Cervix Completed NCT01266447 Phase 2 Topotecan Hydrochloride;Veliparib

Search NIH Clinical Center for Small Cell Carcinoma

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Cisplatin
CISPLATIN PWDR
Teniposide
Topotecan
Topotecan Hydrochloride

Genetic Tests for Small Cell Carcinoma

Anatomical Context for Small Cell Carcinoma

MalaCards organs/tissues related to Small Cell Carcinoma:

40
Lung, Prostate, Cervix, Breast, Ovary, Bone, Brain

Publications for Small Cell Carcinoma

Articles related to Small Cell Carcinoma:

(show top 50) (show all 6967)
# Title Authors PMID Year
1
Neuroendocrine small cell carcinoma of the cervix: A case report. 61
33767861 2021
2
Nomogram based on nutritional and inflammatory indicators for survival prediction of small cell carcinoma of the esophagus. 61
33418231 2021
3
Morphological, immune and genetic features in biopsy sample associated with the efficacy of pembrolizumab in patients with non-squamous non-small cell lung cancer. 61
32997195 2021
4
Hereditary ovarian tumour syndromes: current update on genetics and imaging. 61
33353730 2021
5
Clinical implications of lung neuroendocrine neoplasm classification. 61
33306420 2021
6
Stage IVA cervical cancer: outcomes of disease related complications and treatment. 61
32920534 2021
7
Clinicopathologic and Molecular Cytogenetic Analysis of 8 Cases With Uterine Cervical Ewing Sarcoma: Case Series With Literature Review. 61
33538423 2021
8
Rapid on-site evaluation of touch imprints of biopsies improves the diagnostic yield of transbronchial biopsy for endoscopically nonvisible malignancy: a retrospective study. 61
33388779 2021
9
LEUCOSELECT PHYTOSOME MODULATES SERUM EICOSAPENTAENOIC ACID, DOCOSAHEXAENOIC ACID and PROSTAGLANDIN E3 IN A PHASE 1 LUNG CANCER CHEMOPREVENTION STUDY. 61
33707173 2021
10
Diffusion Tensor Imaging Can Discriminate the Primary Cell Type of Intracranial Metastases for Patients with Lung Cancer. 61
33658441 2021
11
Exploring the resistance mechanisms of second-line osimertinib and their prognostic implications using next-generation sequencing in patients with non-small-cell lung cancer. 61
33744716 2021
12
Transcriptional mediators of treatment resistance in lethal prostate cancer. 61
33664492 2021
13
Single-Cell Transcriptomics Reveal Treatment Effects in Prostate Cancer. 61
33712490 2021
14
Remarkable response of non-small cell lung cancer to nintedanib treatment in a patient with idiopathic pulmonary fibrosis. 61
33742758 2021
15
Recent advances and current controversies in lung neuroendocrine neoplasms✰. 61
33810912 2021
16
Novel Resistance Mechanisms Including L1196Q, P1094H, and R1248_D1249 Insertion in Three Patients With NSCLC After ALK Tyrosine Kinase Inhibitor Treatment. 61
33166721 2021
17
Fertility preservation in rare ovarian tumors. 61
33649010 2021
18
Update on SWI/SNF-related gynecologic mesenchymal neoplasms: SMARCA4-deficient uterine sarcoma and SMARCB1-deficient vulvar neoplasms. 61
33252159 2021
19
A toehold-mediated strand displacement cascade-based DNA assay method via flow cytometry and magnetic separation. 61
33534873 2021
20
The functional landscape of Golgi membrane protein 1 (GOLM1) phosphoproteome reveal GOLM1 regulating P53 that promotes malignancy. 61
33649292 2021
21
Atezolizumab-associated Dermatomyositis in Advanced Lung Small-cell Carcinoma. 61
33776010 2021
22
Clinicopathological and immunohistochemical study of pulmonary neuroendocrine tumors - A single-institute experience. 61
33687006 2021
23
Optimal treatment strategies for small cell carcinoma of the uterine cervix: A retrospective multi-center study (KROG 19-03). 61
33545454 2021
24
Three novel furospirostanol glycosides and a steroidal alkaloid glycoside from the bulbs of Fritillaria camtschatcensis (L.) Ker Gawl., and their cytotoxicity. 61
33715543 2021
25
Ovarian pulmonary-type small cell carcinoma diagnosed by means of ascitic fluid cytology: A case report with immunocytochemical analysis. 61
32989845 2021
26
Major Pathologic Response in Patients Treated for Non-small Cell Carcinoma of the Lung: Is There a Magic Number in the Histologic Sections to Be Evaluated? 61
33405399 2021
27
SMARCA4 (BRG1) and SMARCB1 (INI1) expression in TTF-1 negative neuroendocrine carcinomas including merkel cell carcinoma. 61
33581550 2021
28
Current recommendations for clinical surveillance and genetic testing in rhabdoid tumor predisposition: a report from the SIOPE Host Genome Working Group. 61
33532948 2021
29
De novo neuroendocrine transdifferentiation in primary prostate cancer-a phenotype associated with advanced clinico-pathologic features and aggressive outcome. 61
33586037 2021
30
Re-assigning the histologic identities of COV434 and TOV-112D ovarian cancer cell lines. 61
33328126 2021
31
Atypical teratoid/rhabdoid tumors (ATRTs) with SMARCA4 mutation are molecularly distinct from SMARCB1-deficient cases. 61
33331994 2021
32
Haematological toxicity of pemetrexed in patients with metastatic non-squamous non-small cell carcinoma of lung with third-space fluid. 61
33338923 2021
33
Small cell lung cancer with thyroid gland oligometastasis: A case report. 61
33319473 2021
34
miR-31 Displays Subtype Specificity in Lung Cancer. 61
33558335 2021
35
Dysgerminoma of the Ovary: An Analysis of 140 Cases Emphasizing Unusual Microscopic Findings and Resultant Diagnostic Problems. 61
33577182 2021
36
Efficacy of rapid on-site cytological evaluation (ROSE) by a pulmonologist in determining specimen adequacy and diagnostic accuracy in interventional diagnosis of lung lesions. 61
33527860 2021
37
Influence of preanalytical variables on performance of delta-like protein 3 (DLL3) predictive immunohistochemistry. 61
32488689 2021
38
Small cell carcinoma of the cervix complicated by syndrome of inappropriate antidiuretic hormone secretion: a case report. 61
33596689 2021
39
Small Cell Carcinoma of Ovary, Hypercalcemic Type: Cytologic, Histopathologic, and Immunohistochemical Landscapes of a Rare Case. 61
32750414 2021
40
Safety and efficacy of administering reduced doses of pegylated recombinant human granulocyte-colony stimulating factors in patients treated with cisplatin and etoposide for small cell carcinoma: A retrospective study. 61
33590721 2021
41
A Rare Case of Gallbladder Small Cell Carcinoma. 61
32394121 2021
42
Glioblastoma mimicking metastatic small cell carcinoma: A case report with ultrastructural findings. 61
33609337 2021
43
Results from a biomarker study to accompany a phase II trial of RRx-001 with reintroduced platinum-based chemotherapy in relapsed small cell carcinoma. 61
33306414 2021
44
Treatment Outcomes for Small Cell Carcinoma of the Bladder: Results From a UK Patient Retrospective Cohort Study. 61
33561506 2021
45
A phase II trial of durvalumab and tremelimumab in metastatic, non-urothelial carcinoma of the urinary tract. 61
33382520 2021
46
Ovarian small cell carcinoma, hypercalcemic type: rare and aggressive tumor. 61
33397715 2021
47
Salivary duct carcinoma and small cell carcinoma ex-pleomorphic adenoma: A heretofore undescribed entity and the naming conundrum: MiNEN, combined, collision, or composite tumor? 61
33741286 2021
48
Vascular patterns on narrow band imaging (NBI) video bronchoscopy of lung cancer patients and its relationship with histology: an analytical cross-sectional study. 61
33660246 2021
49
Analysis of Molecular Mechanism of YiqiChutan Formula Regulating DLL4-Notch Signaling to Inhibit Angiogenesis in Lung Cancer. 61
33628824 2021
50
Patient with EGFR-mutant lung cancer harboring de novo MET amplification successfully treated with gefitinib combined with crizotinib. 61
33454089 2021

Variations for Small Cell Carcinoma

Expression for Small Cell Carcinoma

Search GEO for disease gene expression data for Small Cell Carcinoma.

Pathways for Small Cell Carcinoma

Pathways related to Small Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.31 PTPRC NCAM1 KRT7 KRT20 KRT19 KRAS
2 12.59 TP53 PTEN KRAS KLK3 KIT EGFR
3
Show member pathways
12.55 TP53 PTEN KRAS KIT EGFR
4
Show member pathways
12.49 TP53 TMPRSS2 PTEN KRAS KLK3 EGFR
5
Show member pathways
12.48 TP53 PTEN KRAS EGFR BRCA2
6 12.39 SYP NKX2-1 NCAM1 ENO2 CALCA
7
Show member pathways
12.37 TP53 SMARCA4 PTEN KRAS KIT EGFR
8
Show member pathways
12.18 TP53 PTEN KRAS EGFR
9
Show member pathways
12.15 TP53 PTEN KLK3 EGFR
10 11.87 KRT20 KRT19 KRAS EGFR
11 11.83 TP53 SMARCA4 PTEN EGFR
12 11.71 TP53 PTEN KRAS EGFR
13
Show member pathways
11.68 TP53 SMARCA4 BRCA2
14 11.66 PTPRC NCAM1 KIT
15 11.64 SYP SMARCA4 NCAM1
16 11.6 PTPRC NCAM1 KIT
17 11.59 TP53 KRAS EGFR
18 11.29 TP53 SMARCA4 PTEN KRAS EGFR BRCA2
19 11.2 TP53 PTEN KRAS KIT EGFR

GO Terms for Small Cell Carcinoma

Cellular components related to Small Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasmic side of plasma membrane GO:0009898 8.8 PTPRC PTEN KIT

Biological processes related to Small Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.88 TP53 PTEN NKX2-1 KRAS KIT
2 viral process GO:0016032 9.63 TP53 PTPRC NCAM1 KRT7 KRT19 EGFR
3 hematopoietic progenitor cell differentiation GO:0002244 9.58 TP53 PTPRC KIT
4 positive regulation of MAP kinase activity GO:0043406 9.54 KRAS KIT EGFR
5 tongue development GO:0043586 9.46 KIT EGFR
6 bone marrow development GO:0048539 9.43 TP53 PTPRC
7 mast cell chemotaxis GO:0002551 9.32 KIT CHGA
8 positive regulation of phospholipase C-activating G protein-coupled receptor signaling pathway GO:1900738 9.26 GRP CHGA
9 response to gamma radiation GO:0010332 9.13 TP53 PTPRC BRCA2
10 mast cell cytokine production GO:0032762 8.62 KIT CHGA

Molecular functions related to Small Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.23 TP53 SYP PTEN NCAM1 KRAS EGFR

Sources for Small Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....